# *Plasmodium knowlesi* infection is associated with elevated circulating biomarkers of brain injury and endothelial activation

- 1
- 2 Cesc Bertran-Cobo<sup>1,2,3 ]</sup>, Elin Dumont<sup>1 ]</sup>, Naqib Rafieqin Noordin<sup>4</sup>, Meng-Yee Lai<sup>4</sup>, William
- Stone<sup>1</sup>, Kevin KA Tetteh<sup>1ψ</sup>, Chris Drakeley<sup>1</sup>, Sanjeev Krishna<sup>4,5,6,7</sup>, Yee-Ling Lau<sup>4</sup><sup>+\*</sup>, Samuel C
   Wassmer<sup>1</sup><sup>†</sup>\*
- 5
- <sup>6</sup> <sup>1</sup>Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK
- 7 <sup>2</sup>Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa
- 8 <sup>3</sup>Neuroscience Institute, University of Cape Town, Cape Town, South Africa
- <sup>9</sup> <sup>4</sup>Department of Parasitology, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia
- 10 <sup>5</sup>Institut Für Tropenmedizin, Eberhard Karls Universität Tübingen, Tübingen, Germany
- <sup>6</sup>Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon
- <sup>12</sup> <sup>7</sup>Clinical Academic Group in Institute for Infection & Immunity, St George's University of London,
- 13 London, UK
- <sup>14</sup> <sup>Ψ</sup> Current affiliation: FIND, Campus Biotech, Chemin des Mines 9, 1202, Geneva, Switzerland
- 15  $\Box$  These authors share first authorship.
- 16 <sup>†</sup>These authors share last authorship.
- 17
- 18 **\* Correspondence:**
- 19 Prof Dr Yee-Ling Lau, Universiti Malaya, Kuala Lumpur, Malaysia
- 20 lauyeeling@um.edu.my
- 21 Dr Samuel C Wassmer, London School of Hygiene and Tropical Medicine, London, UK
- 22 Sam.Wassmer@lshtm.ac.uk
- 23
- 24 Keywords: *Plasmodium knowlesi*, malaria, brain, vascular dysfunction, Malaysia
- 25

#### 26 Abstract

Introduction: Malaria remains a major public health concern with substantial morbidity and mortality worldwide. In Malaysia, the emergence of *Plasmodium knowlesi* has led to a surge in zoonotic malaria cases and deaths in recent years. Signs of cerebral involvement have been observed in a non-comatose, fatal case of severe knowlesi infection, but the potential impact of this malaria species on the brain remains underexplored. To address this gap, we investigated circulating levels of brain injury, inflammation, and vascular biomarkers in a cohort of knowlesi-infected patients and controls.

<u>Methods</u>: Archived plasma samples from 19 patients with confirmed symptomatic knowlesi infection and 19 healthy, age-matched controls from Peninsular Malaysia were analysed. A total of 52 plasma biomarkers of brain injury, inflammation, and vascular activation were measured using Luminex and SIMOA assays. Wilcoxon tests were used to examine group differences, and biomarker profiles were explored through hierarchical clustering heatmap analysis.

39 <u>Results</u>: Bonferroni-corrected analyses revealed significantly elevated brain injury biomarker levels 40 in knowlesi-infected patients, including S100B (p<0.0001), Tau (p=0.0007), UCH-L1 (p<0.0001), 41  $\alpha$ Syn (p<0.0001), Park7 (p=0.0006), NRGN (p=0.0022), and TDP-43 (p=0.005). Compared to 42 controls, levels were lower in the infected group for BDNF (p<0.0001), CaBD (p<0.0001), CNTN1 43 (p<0.0001), NCAM-1 (p<0.0001), GFAP (p=0.0013), and KLK6 (p=0.0126). Hierarchical clustering 44 revealed distinct group profiles for circulating levels of brain injury and vascular activation 45 biomarkers.

46 <u>Conclusions</u>: Our findings highlight for the first time the impact of *Plasmodium knowlesi* infection on 47 the brain, with distinct alterations in cerebral injury and endothelial activation biomarker profiles 48 compared to healthy controls. Further studies are warranted to investigate the pathophysiology and 49 clinical significance of these altered surrogate markers, through both neuroimaging and long-term 50 neurocognitive assessments.

# 51 **1** Introduction

52 Malaria is a life-threatening, vector-borne infection caused by parasites of the genus *Plasmodium* 53 that led to an estimated 249 million cases worldwide and approximately 608,000 deaths in 2022 (1). 54 Malaria is endemic in Southeast Asia, where it poses a significant public health challenge. In 55 Malaysia, P. falciparum and P. vivax have historically been the species responsible for most malaria 56 infections and deaths, but thanks to national efforts in eradicating the disease, no indigenous cases 57 have been reported since 2018 (1). However, an emerging concern in the country is *P. knowlesi* 58 (Pk), a zoonotic species that has become a significant contributor to malaria infections in humans 59 locally (2,3), with a total of 19,625 Pk cases and 57 deaths reported in Malaysia since 2017, 60 including 2,500 cases and 9 deaths in 2022 alone (1). Malaysia accounts for most Pk infections 61 globally, and this species is currently the major cause of human malaria in the country (4-6).

62 One of the most severe manifestations of *Plasmodium falciparum* infection is cerebral malaria, a life-63 threatening neurological complication characterized by coma (7) and pathological hallmarks such as 64 petechial hemorrhages and parasite sequestration in the brain vasculature (8,9). Neurocognitive 65 sequelae are frequent in survivors and can persist long after the infection has been treated (10,11). 66 While cerebral malaria is predominantly associated with P. falciparum (7), recent case reports have 67 highlighted instances of cerebral involvement and severe neurological complications in patients 68 infected with other *Plasmodium* species (12–18). A high proportion of severe *Pk* infections has been 69 reported in Southeast Asia (5,19), as well as fatal cases (18-20). A recent study also showed that, 70 similarly to P. falciparum, Pk-infected erythrocytes are able bind to endothelial cells (21). Post-71 mortem findings in one fatal case of severe *Pk* malaria revealed brain pathology features similar to 72 those seen in fatal falciparum cerebral malaria, including *Pk*-infected erythrocytes sequestration in 73 the microvasculature (18), suggesting that *Pk* malaria may also affect the brain. Remarkably, coma 74 was not observed in this patient (18), which contrasts with the World Health Organization (WHO) 75 definition of cerebral malaria caused by *P. falciparum* (7).

76 We recently reported that patients with severe and uncomplicated falciparum malaria ---and 77 therefore without coma— have a wide range of brain changes detected using magnetic resonance 78 imaging (MRI) (22,23). Severe malaria patients from our cohort had elevated plasma levels of the 79 neurotrophic factor S100 calcium-binding protein β (S100B), a biomarker associated with central 80 nervous system insults (24,25), which correlated with brain MRI features typically found in cerebral 81 malaria (22). Overall, our findings suggest that there is a frequent and unrecognized impact of 82 malaria infection on the brain in *falciparum* malaria, irrespective of coma. These effects are likely 83 aggravated by acute kidney injury (AKI), with potential long-lasting repercussions on quality of life 84 and productivity in survivors (26).

Despite the similar pathologies reported between cerebral malaria and fatal *Pk* infection (18) and the high incidence of kidney dysfunction in severe *Pk* malaria (27), the potential impact of *Pk* infection on the human brain remains largely unexplored. To bridge this important knowledge gap, we quantified plasma biomarkers of brain injury, vascular activation, and inflammation in a cohort of Malaysian *Pk*-infected patients and healthy controls.

# 91 2 Methods

#### 92 **2.1 Participants and samples**

93 This study leveraged archived plasma samples from patients aged 18 years and above with malaria 94 symptoms attending either a government hospital or private clinic in Johor, Selangor, Pahang, 95 Perak, and Trengganu states between December 2019 and January 2023 (Figure 1). Recruitment 96 of community-matched, age-matched uninfected controls was conducted via active screening of 97 individuals from communities in Johor, Selangor, Negeri Sembilan, and Kedah. Subjects were 98 approached for participation if they had no fever, were aged 18 years and above, and were part of 99 any of the considered high-risk groups. A high-risk group is defined as individuals working in 100 proximity with forest and forest fringes, i.e., servicemen, farmers, hunters, and natural resource 101 collectors (2,28).

Data collection procedures are described elsewhere (29). Briefly, samples were acquired using 102 103 EDTA anti-coagulant tubes. Informed consent was obtained prior to sample collection. All 104 participants were allowed sufficient time to consider their participation in the project. Individual data 105 were collected and recorded anonymously. Plasmodium infection and speciation in each collected 106 sample were confirmed by microscopic examination of Giemsa-stained blood smears and nested 107 polymerase chain reaction (PCR) based on the 18S rRNA gene. Out of the 50 individuals sampled 108 as part of the parent project, 38 had associated clinical information needed for this study, including 109 parasitemia. The de-identified Malaysian samples, consisting of 19 infected patients and 19 healthy 110 controls, were analysed.

# 111 **2.2 Biomarker panel selection**

A total of 52 plasma biomarkers were selected, including 21 markers of brain alterations or cerebral injury, 21 markers of infection and immune activation, and 10 vascular biomarkers. Our literature review-based selection followed the assumption that any plasma biomarker ever reported to be altered in any species of human malaria could potentially be altered in our cohort of *Pk* patients. For brain injury biomarkers, a second premise applied: since cerebral malaria can cause long-lasting cognitive disorders (10,11), any plasma marker reported to be increased or decreased in cognitively impaired subjects (e.g., neurodegenerative diseases, traumatic brain injury, etc) could also be altered in our patients.

To inform the biomarker panel selection, a systematic search of scientific literature on biomarker plasma levels in human patients was conducted in PubMed database, including all relevant publications from 2010 onwards. The results of this systematic search are comprehensively summarized in **Table 1** (brain injury biomarkers), **Supplementary Table 1** (infection and immune activation biomarkers) and **Supplementary Table 2** (vascular biomarkers).

# 125 **2.3** Measurement of plasma biomarker levels via Luminex and SIMOA assays

126 Thirty-eight biomarkers were analysed using the customizable Human Luminex® Discovery Assay 127 provided by R&D Biotechne (catalogue ref.: LXSAHM): Alpha-Synuclein (αSyn), Amyloid-beta 128 precursor protein (APP), Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), Bone Morphogenetic 129 Protein 9 (BMP-9), Calbindin D (CaBP), Chemokine Ligand 2 (CCL2), Chemokine Ligand 4 (CCL4), 130 Chemokine Ligand 5 (CCL5), Chemokine Ligand 18 (CCL18), Contactin-1 (CNTN1), C-Reactive 131 Protein (CRP), Enolase 2 / Neuron-specific Enolase (ENO2/NSE), Fetuin A, Granulocyte-132 Macrophage Colony-Stimulating Factor (GM-CSF), Interferon Gamma (IFN-y), Intercellular 133 Adhesion Molecule 1 (ICAM-1), Interleukin 1 alpha (IL-1  $\alpha$ ), Interleukin 1 beta (IL-1  $\beta$ ), Interleukin 134 1RA (IL-1RA), Interleukin 2 (IL-2), Interleukin 4 (IL-4), Interleukin 6 (IL-6), Interleukin 8 (IL-8), Interleukin 10 (IL-10), Interleukin 17 (IL-17A), Lipocalin-2 (NGAL), Myeloperoxidase (MPO), 135 136 Osteopontin (OPN), Parkinsonism associated deglycase (Park7), Platelet-Derived Growth Factor AA 137 (PDGF-AA) and BB (PDGF-BB), Receptor for Advanced Glycation Endproducts (RAGE), Serine 138 Proteinase Inhibitor<sup>®</sup>clade E1 (Serpin E1), Tumour Necrosis Factor alpha (TNF-α), Vascular Cell

# Adhesion Molecule (VCAM-1), Vascular Endothelial Growth Factor (VEGF), and von Willebrand Factor A2 domain (vWF-A2).

Additionally, 10 biomarkers were analysed using the Neuroscience 18-plex Human ProcartaPlex<sup>TM</sup> Panel assay provided by ThermoFisher Scientific Invitrogen<sup>TM</sup> (catalogue ref.: EPX180-15837-901): Amyloid beta (1-42) ( $A\beta_{(1-42)}$ ), Brain-Derived Neurotrophic Factor (BDNF), Kallikrein 6 (KLK6), Migration Inhibitory Factor (MIF), Nerve Growth Factor beta (NGF- $\beta$ ), Neural Cell Adhesion Molecule (NCAM-1), Neurogranin (NRGN), S100 calcium-binding protein  $\beta$  (S100 $\beta$ ), TAR DNAbinding protein 43 (TDP-43), and Chitinase-3-like protein 1 (YKL-40).

147 Serum levels of biomarkers screened via the Human Luminex® Discovery Assay (#LXSAHM) and 148 the Neuroscience 18-plex Human ProcartaPlex<sup>™</sup> Panel (#EPX180-15837-901) were measured 149 using a MAGPIX© bioanalyzer, according to manufacturer's instructions. Singlicate measurements 150 were taken of each sample. Sample concentrations were extrapolated from a standard curve, fitted 151 using a 6-parameter logistic algorithm. Luminex technology is a multiplex assay platform that allows 152 for the simultaneous measurement of multiple biomarkers in a single plasma sample and can detect 153 molecule concentrations in the picogram range. The use of Luminex technology in the study of 154 biomarkers of brain injury is widely extended (30) due to its high sensitivity and reproducibility.

155 Lastly, 4 brain injury biomarkers were analysed using the highly sensitive single molecule 156 immunoassay (SIMOA), using the Human Neurology 4-Plex A assay provided by Quanterix 157 (catalogue ref.: 102153): Neurofilament light (NfL), total Tau protein (Tau), Glial Fibrillary Acidic 158 Protein (GFAP), and Ubiguitin Carboxyl-terminal Hydrolase L1 (UCH-L1). Levels of biomarkers 159 screened via the SIMOA Human Neurology 4-Plex A assay (#102153) were measured using a 160 SIMOA HD-X<sup>™</sup> Analyzer (Quanterix), according to manufacturer's instructions. Briefly, samples 161 were thawed at 21°C, and centrifuged at 10,000 RCF for five minutes at the same temperature. On-162 board the instrument, samples were diluted 1:4 with sample diluent and bound to paramagnetic 163 beads coated with a capture antibody specific for human GFAP, NfL, Tau, and UCH-L1. GFAP, NfL,

164 Tau, and UCH-L1 bound beads were then incubated with a biotinylated GFAP, NfL, Tau, and UCH-165 L1 detection antibodies in turn conjugated to streptavidin-β-galactosidase complex that acts as a 166 fluorescent tag. Subsequent hydrolysis reaction with a resorutin  $\beta$ -D-galactopyranoside substrate 167 produces a fluorescent signal proportional to the concentration of GFAP. NfL. Tau. and UCH-L1 168 present. Singlicate measurements were taken of each sample. Sample concentrations were 169 extrapolated from a standard curve, fitted using a 4-parameter logistic algorithm. SIMOA is an 170 ultrasensitive digital immunoassay that allows for the detection and quantification of low-abundance 171 plasma biomarkers with sub-femtomolar sensitivity, high specificity, and high reproducibility (31).

### 172 **2.4** Serological assessment of malaria exposure via Luminex immunoassay

173 As past infections with *Plasmodium* spp. could also influence observed biomarker levels across 174 participants, total IgG antibody responses of all *Pk*-infected patients and healthy controls were 175 measured using a multiplex bead-based immunoassay built on Luminex® xMAP® technology to 176 assess previous exposure to P. knowlesi as well as P. falciparum, P. vivax, P. malariae, and P. 177 ovale. Sera were screened against a previously optimised panel of 14 blood-stage antigens 178 representing varied markers of malaria exposure, listed in Supplementary Table 3. This 179 incorporated 6 Pk antigens: PkAMA1 and PkMSP1<sub>19</sub>, historical (long-term) exposure markers that 180 can persist in blood for several years with repeated infections, PkSera3 Ag2 and PkSSP2/TRAP, 181 which have previously been utilised as markers in seroprevalence studies on Malaysian populations 182 (32-34), and Pk1 and Pk8, exploratory antigens that demonstrated high immunogenicity in 183 preliminary data from assay screenings of pooled sera from *Pk*-infected Malaysian hyperimmune 184 individuals (K. Tetteh, personal communication). For P. falciparum and P. vivax, markers of historical exposure, Pf / PvMSP119 and Pf / PvAMA1, and markers of recent (short-term) exposure 185 186 known to persist in blood for up to 6-12 months following infection, *Pf*Etramp5 Ag1 and *Pv*RBP 2b, 187 were included (35,36). PmMSP1<sub>19</sub> and PoMSP1<sub>19</sub> were used to assess historical exposure to P. 188 malariae and P. ovale, respectively. Additionally, tetanus toxoid vaccine protein from Clostridium

*tetani* and glutathione-S-transferase (GST) from *Schistosoma japonicum* were included as non malaria internal assay controls (37).

191 The Luminex assay was performed as previously described (38). Briefly, based on previously 192 identified antigen-specific optimal  $EC_{50}$  concentrations, each antigen was covalently coupled to a 193 colour-coded MagPlex® bead region (MagPlex, Luminex Corp., Austin, TX) via N-194 Hydroxysuccinimide/1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (NHS/EDC) chemistry. Test 195 sera were prepared at 1/400 in diluent buffer (1x Phosphate Buffer Saline (PBS); 0.05% Tween® 20: 196 0.5% bovine serum albumin; 0.02% sodium azide; 0.1% casein; 0.5% polyvinyl alcohol; 0.5% 197 polyvinylpyrrolidone; 15.25ug/mL E. coli lysate) and incubated at 4°C overnight. Antigen-coupled 198 beads were incubated with 50uL of diluted samples and incubated for 90 minutes at room 199 temperature with shaking at 600 RPM before incubation with 50µL of 1/200 R-Phycoerythrin-200 conjugated AffiniPure  $F(ab')_2$ Fragment Goat Anti-Human lgG secondarv antibodv 201 (JacksonImmunoResearch; 109-116-098) for 90 minutes under the same conditions (38).

Pooled sera from hyperimmune individuals in Malaysia (Pk+), Tanzania (CP3), and Peru (S1) were 202 203 included as Pk, P. falciparum, and P. vivax positive controls, respectively, in 6-point 5-fold serial 204 dilution curves (1/10 - 1/31250). Commercial WHO reference reagents for anti-P. falciparum 205 (10/198) human serum and anti-P. vivax (19/198) human plasma were also added as positive 206 controls at 1/400 and 1/4000. Public Health England (PHE) malaria naïve human sera (n=30) were 207 included as negative controls at 1/400. Two wells of diluent buffer served as blank controls to allow 208 subtraction of background signal. The plates were read using the MAGPIX© instrument (Luminex 209 Corp., Austin, TX) with the raw data recorded as Median Fluorescent Intensity (MFI) values using an 210 acquisition target of ≥30 beads per region per well. The data were background-adjusted and 211 normalised as described by Wu et al (38).

# 212 2.5 Statistical analysis

Sociodemographic characteristics of the participants were reported as mean ( $\pm$ SD) for continuous data, or absolute frequencies (%) for categorical data. Continuous data was assessed for normality using Shapiro-Wilk tests. Comparisons between *Pk*-infected cases and healthy controls were made using *t*-tests or Wilcoxon tests for normally and non-normally distributed continuous data, respectively, and  $\chi^2$  tests for categorical data.

Differences in levels of individual biomarkers between *Pk*-infected patients and controls were examined using two-tailed *t*-tests and Wilcoxon tests for normally and non-normally distributed data, respectively. Bonferroni correction for multiple comparisons was applied. Correlation matrixes were used to visualize the relationships between biomarker levels in both groups, with previous data scaling. Any potential correlations between biomarker levels and demographic and clinical parameters such as age and parasitemia were evaluated using Spearman's rank correlation coefficient.

To elucidate potential profiles of biomarker levels that could distinguish between infected patients and controls, a hierarchical clustering heatmap analysis was performed, prior scaling of biomarker data. This provided a visual representation of the relationships between individuals based on the similarity of their biomarker profiles. Initially, the analysis was conducted on the entire set of biomarkers to comprehensively explore the clustering patterns within the dataset. Subsequently, the clustering analysis was applied separately to subsets of biomarkers representing brain injury, infection and immunity, and vascular biomarkers.

To assess malaria exposure, a hierarchical clustering heatmap was similarly performed to allow visual comparison of individual antibody responses to *Pk*-specific antigen profiles across study participants. Comparisons of group means of MFI responses between *Pk*-infected cases and healthy controls were conducted using the non-parametric Kruskal-Wallis test with Dunn's correction for multiple comparisons applied.

- 237 Statistical analyses were performed in R (version 4.3.1) with RStudio software (version 2023.09.1-
- 494). Data was visualized in R (version 4.3.1) with RStudio software (version 2023.09.1-494) and
- 239 GraphPad Prism 10. P values of less than 0.05 (two-tailed) were considered statistically significant.

#### 240 **3** Results

#### 241 **3.1 Cohort characteristics**

All participants in our sub-study were male (N=38, 100%). Both *Pk*-infected patients and communitymatched, age-matched uninfected controls had an average age of 39 ( $\pm$ 15) years. In the *Pk*-infected group, patients presented with median parasitemia 15,200.00 parasites/µL and 26,746.00 interquartile range.

# **3.2** Concentrations of individual markers between *Pk*-infected patients and controls

247 Biomarkers of brain injury: Bonferroni-corrected analyses revealed significantly higher plasma levels 248 of the following brain injury biomarkers in the *Pk*-infected group, compared with uninfected controls: 249 Tau (p=0.0007), UCH-L1 (p<0.0001), αSyn (p<0.0001), Park7 (p=0.0006), NRGN (p=0.0022), and 250 TDP-43 (p=0.005). In contrast, levels of the following biomarkers were found to be significantly lower 251 in the Pk-infected group when compared with uninfected controls: CaBD (p<0.0001), CNTN1 252 (p<0.0001), NCAM-1 (p<0.0001), BDNF (p<0.0001), GFAP (p=0.0013), and KLK6 (p=0.0126). 253 Results obtained on CaBD and CNTN1 levels revealed clear cutoff values that allowed for subject 254 classification based on infection status: All Pk-infected patients (19/19, 100%) presented with plasma CaBD levels below 1,400pg/mL or CNTN1 levels below 12,500pg/mL, whereas 255 256 concentrations in all uninfected controls (19/19, 100%) were above 1,400pg/mL for CNTN1 and 257 above 15,000pg/mL for CNTN1, respectively (Figure 2, Supplementary Table 4).

Since S100B and  $A\beta_{(1-42)}$  plasma levels were below the range of detection in most uninfected subjects, we first compared the proportion of individuals with detectable levels of these biomarkers in each group using a Chi-square test with Yates' correction. The percentage of participants with plasma levels within the range of detection was significantly higher in the *Pk*-infected group (19/19, 100%) than in the uninfected control group (4/19, 21.05%) (p<0.0001). Similarly for  $A\beta_{(1-42)}$ , the

- proportion of individuals with detectable plasma levels in the *Pk*-infected group (17/19, 89.47%) was
- significantly higher compared with their uninfected peers (7/19, 36.84%) (p= 0.0025).

To enable group comparisons for these two biomarkers, participants with values below the range of detection were assigned a numerical value corresponding to half the value of the lower threshold of detection. According to the manufacturer's information, these values were 27.31 pg/mL for S100B and 0.22 pg/mL for A $\beta_{(1-42)}$ . Achieved this, Wilcoxon tests revealed significantly higher plasma S100B levels in the *Pk*-infected group, which survived Bonferroni correction for multiple comparisons (p<0.0001), whereas no significant group differences were found for A $\beta_{(1-42)}$  plasma levels.

<u>Biomarkers of infection and immune activation</u>: Group differences in plasma levels were found after correction for multiple comparisons. IL-1RA (p<0.0001), IL-10 (p<0.0001), and MPO levels (p=0.0314) were significantly higher in the *Pk*-infected group when compared with their uninfected peers, whereas CCL4 (p<0.0001), CCL5 (p<0.0001), CRP (p=0.0280), and RAGE levels (p=0.0025) were significantly lower (**Supplementary Figure 1**, **Supplementary Table 4**).

<u>Biomarkers of vascular activation and injury</u>: Ang-2/Ang-1 ratios (p<0.0001) and VCAM-1 levels (p=0.0001) were significantly higher in *Pk*-infected patients compared with uninfected controls, while Ang-1 (p<0.0001), BMP-9 (p<0.0001), PDGF-AA and -BB (p<0.0001), and Serpin E1 levels (p<0.0001) were significantly lower (**Supplementary Figure 2**, **Supplementary Table 4**).

# **3.3** Hierarchical clustering of samples based on biomarker blood levels

Hierarchical clustering heatmap analyses revealed distinct group profiles for brain injury biomarkers (**Figure 3A**). Most infected individuals clustered together (17/19, 89.47%), indicating a cohesive pattern of elevated levels of Park7, S100B,  $\alpha$ Syn, and TDP-43. Two infected individuals exhibited atypical clustering with the healthy controls, suggesting a subgroup with a distinct biomarker profile. In the control group (19/19, 100%), certain biomarkers, including BDNF, CaBD, CNTN1, and GFAP, displayed higher levels and clustered together, representing a baseline biomarker profile in healthy
individuals. As mentioned, two infected individuals (2/19, 10.53%) clustered with the control group in
this category, indicating potential overlap or similarity in the levels of these specific biomarkers
between infected and control individuals.

Clustering of biomarkers associated with infection and immune activation did not reveal distinct separation between the two groups (**Figure 3B**). Higher levels of IL-1RA and MPO predominantly clustered in the infected group (17/19, 89.47%), and two control individuals also exhibited this pattern (2/19, 10.53%). One infected individual (1/19, 5.26%) displayed very high levels of IL-1 $\beta$ , GM-CSF, TNF- $\alpha$ , CCL4, and CCL2. Another infected individual (1/19, 5.26%) exhibited very high levels of OPN and IL-10. Additionally, one control individual showed high levels of IL-6 (1/19, 5.26%).

Lastly, clustering of vascular biomarkers revealed clear and distinctive group profiles (**Figure 3C**). In the control group (19/19, 100%), a cohesive cluster formed by high levels of PDGF AA, Ang-1, PDGF BB, Serpin E1, and BMP-9 was observed. Conversely, in the infected group (19/19, 100%), a distinct cluster of higher levels of VCAM-1 and the Ang-2/Ang-1 ratio was identified.

302 Correlations between biomarkers in each group can be observed in **Supplementary Figure 3**.

# **303 3.4** Correlation of biomarker levels with age and parasitemia

No significant correlations were identified between the levels of any of the examined biomarkers and the age of participants within each respective group, as illustrated in **Supplementary Figure 4**. Furthermore, within the *Pk*-infected group, no significant correlations were observed between biomarker levels and the percentage of parasitemia (**Supplementary Figure 5**).

# 308 **3.5** Serological markers of previous malaria exposure

309 Overall, the majority of participants generated low antibody responses across Pk, P. vivax, P. 310 falciparum, P. ovale, and P. malariae antigens with the exception of a few high responders 311 (Supplementary Figure 6). Clustering of exposure markers in the hierarchical heatmap analysis did 312 not reveal distinct separation between responses of *Pk*-infected patients and uninfected controls 313 (Supplementary Figure 7). Among *Pk* antigens, uninfected controls exhibited higher responses 314 against Pk8 (p<0.0001), PkSERA3 Ag2 (p=0.0406), and Pk1 (p=0.0250) than Pk-infected patients, 315 but no differences were observed for PkAMA1 (p>0.9999), PkMSP1<sub>19</sub> (p=0.7778), or PkSSP2 316 (p=0.2592).

#### 317 **4 Discussion**

318 Our study sheds light on the potential neurological implications of *Pk* infection in Malaysia. Through 319 the investigation of circulating levels of brain injury, inflammation, and vascular biomarkers in Pk-320 infected patients compared to healthy controls, we uncovered compelling evidence suggesting a 321 significant impact of Pk infection on brain health. In line with previous reports suggesting 322 neurological involvement in severe malaria, our findings demonstrate increased levels of several 323 biomarkers associated with cerebral injury in *Pk*-infected patients. Notably, elevated levels of 324 S100B, Tau, UCH-L1, αSyn, Park7, NRGN, and TDP-43 signify potential brain damage in response 325 to *Pk* infection in our cohort.

326 Alterations in circulating levels of S100B, Tau, and UCH-L1 have been documented in previous 327 investigations of severe malaria. S100B, an abundant neurotrophic factor predominantly expressed 328 in astrocytes, serves as a biomarker of blood-brain barrier permeability and central nervous system 329 injury (39). Our group reported increased plasma levels of \$100B in Indian patients with falciparum 330 severe malaria compared to uncomplicated cases (40). Similarly, levels of microtubule-associated 331 protein Tau, a neuropathological hallmark of Alzheimer's Disease and a biomarker for brain injury 332 (41), were found increased in the plasma of Ugandan children with severe falciparum malarial 333 anemia or cerebral malaria compared to uninfected controls. In cerebral malaria cases, Tau levels 334 correlated with mortality and persistent neurocognitive impairment in survivors (42). Lastly, plasma levels of the ubiquitin-protein hydrolase UCH-L1, a marker of neuronal damage (43) were 335 336 significantly higher in Ugandan children with falciparum cerebral malaria and severe malarial anemia 337 compared with asymptomatic community children. The elevated plasma levels were associated with 338 surrogate markers of blood-brain barrier dysfunction and cognitive deficits over follow-up (44). Our 339 findings of increased S100B, Tau, and UCH-L1 plasma levels during Pk infection align with these 340 observations, suggesting potential cerebral involvement, neuronal injury, and blood-brain barrier 341 disruption in knowlesi malaria pathogenesis.

342 In broader clinical contexts, elevated circulating biomarkers in our Pk-infected cohort have been 343 associated with diverse conditions and are used as indicators of brain injury or dysfunction. For 344 instance, patients with Parkinson's Disease had significantly higher plasma levels of synaptic vesicle 345 trafficking regulator  $\alpha$ Syn compared to healthy controls (45), and elevated levels of post-synaptic 346 protein NRGN were associated with mild to acute traumatic brain injury (46,47), as well as neonatal 347 encephalopathy (48). The increased levels of  $\alpha$ Syn and NRGN in our *Pk*-infected patients suggest 348 potential neurological implications, prompting further investigation into the underlying mechanisms of 349 knowlesi malaria pathogenesis and their clinical significance over time.

350 In our study, several biomarkers were significantly decreased in *Pk*-infected individuals compared to 351 healthy controls, including GFAP, BDNF, CaBD, CNTN1, NCAM-1, and KLK6. The astrocytic 352 intermediate filament protein GFAP, used in clinical settings to assess severity of traumatic brain 353 injury (49), glymphatic function (50), and neurodegeneration (51,52), was not found to be elevated in 354 Ugandan children with falciparum cerebral malaria and severe malarial anemia (44). In contrast, the 355 observed differences in GFAP levels in our groups may suggest altered astroglial and/or glymphatic 356 functions in infected participants, supporting our hypothesis of cerebral involvement in Pk malaria. 357 Conversely, plasma levels of the neurotrophic factor BDNF, reported to be increased in early 358 Alzheimer's disease (53) and decreased in multiple sclerosis (54), were also lower in our study 359 participants, potentially indicating dysregulated neuroprotective mechanisms during Pk infection. 360 Furthermore, increased cerebrospinal fluid levels of CaBD, a protein involved in calcium 361 homeostasis and neuronal signalling, were associated with risk of dementia in cognitively normal 362 patients (55). CNTN1 and NCAM-1, two crucial factors for neural development and synaptic 363 formation, were decreased in our Pk-infected patients. Downregulated CNTN1 serum levels 364 predicted cognitive and motor declines in patients with Parkinson's Disease (56), while lower plasma 365 NCAM-1 levels correlated with cognitive impairment (57,58). Lastly, plasma levels of the 366 neuroinflammation modulator KLK6 were significantly increased in patients with advanced 367 Alzheimer's Disease compared with healthy controls (59). Although challenging to interpret, these

results suggest cerebral involvement during *Pk* infection and a potential risk of cognitive decline, indicating a complex interplay between neuroinflammatory and neuroprotective mechanisms that warrant further investigation.

371 Despite our expectations based on existing malaria literature (Table 1), we did not observe 372 significant group differences in levels of some biomarkers, such as the iron-trafficking protein 373 Lipocalin-2 (NGAL), a recognized biomarker of neuroinflammation (60). Elevated plasma NGAL 374 levels were associated with cerebral malaria in adult patients from India and distinguished between 375 fatal and nonfatal outcomes (61). Similarly, plasma NfL levels in Mozambican children with 376 uncomplicated and severe falciparum malaria showed no baseline group differences, but a 377 significant increase over time, particularly in severe malaria cases with neurological symptoms, 378 suggesting NfL as a potential follow-up biomarker of brain injury in malaria (62). Additionally, the 379 glycoprotein Fetuin A was previously reported as elevated in serum from Malaysian patients with Pk 380 malaria compared to uninfected controls (63). Lastly, plasma levels of the neurotrophic factor CNTF 381 were significantly reduced in Thai patients with cerebral malaria or severe malaria with renal failure. 382 compared to severe malaria cases without cerebral or renal involvement (64). Our findings, 383 diverging from anticipated outcomes, underscore the complexity of biomarker dynamics in infections 384 with different *Plasmodium* species and emphasize the need for further exploration in the context of 385 Pk malaria.

386 In our hierarchical clustering analysis, we observed distinct group profiles for brain injury biomarker 387 levels, indicating differences between Pk-infected patients and healthy controls. Most infected 388 individuals clustered together with elevated levels of specific biomarkers such as S100B,  $\alpha$ Syn, 389 Park7, and TDP-43, suggesting a cohesive pattern of cerebral injury. However, two infected 390 individuals exhibited an atypical clustering with the healthy controls, hinting at potential subgroup 391 variability within the infected cohort, or different stages of disease progression. Conversely, in the 392 control group, several biomarkers including BDNF, GFAP, CaBD, and CNTN1 displayed higher 393 levels and clustered together, representing a baseline biomarker profile in healthy individuals. As

mentioned, two infected individuals clustered with the control group in this category, indicatingpotential overlap or milder infection.

396 Clustering of vascular biomarkers revealed clear and distinctive group profiles. Uninfected 397 individuals formed a cohesive cluster with high levels of PDGF AA, Ang-1, PDGF BB, Serpin E1, 398 and BMP-9, revealing a healthy, baseline vascular profile. Conversely, the infected group cluster 399 had high levels of VCAM-1 and Ang-2/Ang-1 ratio, indicative of vascular involvement and endothelial 400 activation during Pk infection. The elevated Ang-2/Ang-1 ratio observed in our infected group aligns 401 with findings from previous studies on severe malaria caused by other *Plasmodium* species (65–70). 402 Similarly, increased levels of VCAM-1 have been reported in both falciparum and vivax malaria 403 infections (71,72). In contrast to brain injury and vascular biomarker profiles, hierarchical clustering 404 of biomarkers associated with infection and immune activation did not reveal distinct separation 405 between the two groups.

406 Lastly, total IgG antibody responses observed against *Plasmodium* spp. antigens, including *Pk*, 407 were low not only among most uninfected controls but also Pk-infected patients, and did not form 408 distinct clusters between the two groups. This suggests the cohort was largely malaria naïve, with 409 low reactivity to long-term infection markers Pk/Pv/Pf/Pm/PoMSP1<sub>19</sub> and Pk/Pv/PfAMA1 observed at 410 levels comparable to the PHE malaria naïve controls in all but two Pk-infected patients (73). As 411 naturally acquired responses against these antigens develop cumulatively with repeated exposure, 412 this indicates the occurrence of very few historical Plasmodium infections across participants (74). 413 This could highlight a lack of clinical immunity, rendering *Pk*-infected patients more susceptible to 414 potential malaria complications reflected in the brain and vascular biomarker profiles in this study, 415 though this was not possible to investigate due to insufficient clinical information. The lack of 416 elevated responses to Pk antigens SSP2, SERA3 Ag2, Pk1 and Pk8 may indicate there was 417 inadequate time for *Pk*-infected patients to mount a response prior to the sampling period (32).

Among uninfected controls, serological analyses identified two individuals exhibiting notably higher responses: one control to *Pk* exploratory marker *Pk*8 and *P. vivax* short-term exposure marker *Pv*RBP2b, and another also to *Pv*RBP2b. Although this suggests previous exposures to *Pk* and *P. vivax*, this did not appear to explain any atypical deviations in plasma biomarker levels observed in a minority of individuals in this group.

423 Our study had several limitations. Firstly, the lack of detailed clinical information regarding malaria 424 severity and the presence or absence of renal failure among the Pk-infected group restricts our 425 ability to fully contextualize the observed alterations in brain injury biomarkers. While recent studies 426 have implicated AKI in the pathogenesis of brain injury (40) and long-term neurocognitive seguelae 427 (10,11), we were unable to directly investigate this relationship. Since AKI is a common complication 428 of knowlesi malaria (27), it is likely that similar distant organ pathways are involved, resulting in an 429 exacerbation of the brain changes (26). Secondly, our study did not include long-term follow-up 430 assessments to determine whether the elevated biomarker levels observed in Pk-infected patients 431 return to baseline or exhibit a steady increase over time. This would have been particularly relevant 432 for NfL, which increases in the weeks following cerebral insult and could provide valuable insights 433 into the persistence or resolution of brain injury following Pk infection (43,62). Lastly, a symptomatic, 434 non-malaria control group would allow stronger ascertainment of associations between biomarkers 435 and Pk infection.

436 In conclusion, our study represents the first comprehensive exploration of surrogate markers of cerebral involvement in Pk-infected patients from Malaysia. Through the investigation of circulating 437 438 levels of brain injury, inflammation, and vascular biomarkers in Pk-infected patients compared to 439 healthy controls, we uncovered compelling evidence suggesting a significant impact of Pk infection 440 on brain and vascular health. The identification of distinct patterns in the clustering of biomarkers 441 associated with cerebral injury and endothelial dysfunction highlights the complex interplay between 442 these pathways during *Pk* infection. Our study lays the groundwork for further research to elucidate 443 the pathophysiology of this disease, and its potential long-term effects on the brain. Additional

investigations are urgently needed to assess structural and functional changes in the brain during knowlesi malaria, through both neuroimaging and longitudinal neurocognitive evaluations. Our findings not only contribute to our understanding of *Pk* malaria but may also have future implications for the diagnosis, management, and therapeutic targeting of neurological complications associated with this emerging infectious disease.

# 450 **5** Ethics approval and consent

451 This study has been reviewed and approved by the Medical Research and Ethics Committee of the 452 Ministry of Health Malaysia (reference NMRR ID 22-02557-1KV) and by in the 453 Observational/Interventions Research Ethics Committee at the London School of Hygiene and 454 Tropical Medicine, UK (reference 27902). The shipment of samples from Malaysia to the UK was 455 performed in compliance with national and international regulations in both sites. The samples are 456 registered with the Human Tissue Authority, in accordance with UK national guidelines.

457

# 458 6 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financialrelationships that could be construed as a potential conflict of interest.

461

# 462 **7** Author Contributions

463 **CBC**: conceptualization, methodology, investigation, formal analysis and interpretation, visualization, 464 writing – original draft, review & editing, ED; methodology, formal analysis and interpretation. 465 visualization, writing - review & editing. NRN: conceptualization, methodology, investigation, writing 466 - review & editing. **MYL**: conceptualization, methodology, investigation, writing - review & editing. 467 **KT**: methodology, investigation, resources, and writing – review & editing. **CD**: methodology, 468 investigation, resources, and writing - review & editing. SK: conceptualization, investigation, and writing - review & editing. YLL: conceptualization, methodology, investigation, resources, 469 supervision, and writing - review & editing. SCW: conceptualization, methodology, investigation, 470 471 resources, supervision, and writing – review & editing. All authors approved the final version.

# 473 **8 Funding**

474 SCW is supported by the Medical Research Council UK under award number MR/S009450/1, and 475 the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) 476 under award number U19AI089676. The content is solely the responsibility of the authors and does 477 not necessarily represent the official views of the NIH.

478

# 479 **9** Acknowledgments

We extend our gratitude to the local health officers and personnel from Mersing, Kota Tinggi, and Pejabat Kesihatan Dareah Kota Tinggi (Johor), Kuala Lipis and Kesihatan Betau (Pahang), Sungai Siput (Perak), Kuala Kubu Bharu (Selangor), and Setiu (Trengganu) for their invaluable assistance with sampling. We express our sincere appreciation to Dr Christian Bottomley, Ana Chopo-Pizarro, and Helena Brazal Monzó at LSHTM for their invaluable insights, which greatly enhanced the quality of this research.

486

# 487 **10 References**

- 488 1. WHO (2023). World Health Organization: World Malaria Report 2023.
- 489
  490
  490
  491
  2. Singh B, Sung LK, Matusop A, Radhakrishnan A, Shamsul SSG, Cox-Singh J, *et al.* A large focus of naturally acquired *Plasmodium knowlesi* infections in human beings. *The Lancet* (2004) 363(9414):1017–24.
- 4923.Barber BE, Grigg MJ, Cooper DJ, van Schalkwyk DA, William T, Rajahram GS, et al. Clinical<br/>management of *Plasmodium knowlesi* malaria. Adv Parasitol (2021) 113:45–76.
- 4944.Lai MY, Rafieqin N, Lee PY, Lee Z, Amir Rawa MS, Dzul S, et al. High incidence of Plasmodium495knowlesi malaria compared to other human malaria species in several hospitals in Malaysia. Trop496Biomed (2021) 38(3):248–53.
- 4975.Kotepui M, Kotepui KU, Milanez GD, Masangkay FR. Prevalence of severe Plasmodium knowlesi498infection and risk factors related to severe complications compared with non-severe P. knowlesi and499severe P. falciparum malaria: a systematic review and meta-analysis. Infect Dis Poverty (2020) 9(1):1–50014.

- 5016.Phang WK, Hamid MHA, Jelip J, Mudin RN, Chuang TW, Lau YL, et al. Spatial and Temporal Analysis502of Plasmodium knowlesi Infection in Peninsular Malaysia, 2011 to 2018. International Journal of503Environmental Research and Public Health (2020) 17(24):9271.
- 504 7. Severe malaria. *Trop Med Int Health* (2014) 19 Suppl 1:7–131.
- 5058.Muppidi P, Wright E, Wassmer SC, Gupta H. Diagnosis of cerebral malaria: Tools to reduce506Plasmodium falciparum associated mortality. Front Cell Infect Microbiol (2023) 13:95.
- 507 9. Hadjilaou A, Brandi J, Riehn M, Friese MA, Jacobs T. Pathogenetic mechanisms and treatment targets 508 in cerebral malaria. *Nat Rev Neurol* (2023) 19(11):688–709.
- 50910.Coughlan C, Jäger HR, Brealey D, Carletti F, Hyare H, Pattnaik R, et al. Adult Cerebral Malaria: Acute510and Subacute Imaging Findings, Long-term Clinical Consequences. Clin Infect Dis (2024) 78(2):457–51160.
- 512 11. Ssemata AS, Nakitende AJ, Kizito S, Thomas MR, Islam S, Bangirana P, *et al.* Association of severe
   513 malaria with cognitive and behavioural outcomes in low- and middle-income countries: a meta-analysis
   514 and systematic review. *Malar J* (2023) 22(1):1–12.
- 515 12. Mukhtar MM, Eisawi OA, Amanfo SA, Elamin EM, Imam ZS, Osman FM, *et al. Plasmodium vivax* 516 cerebral malaria in an adult patient in Sudan. *Malar J* (2019) 18(1):316–316.
- 51713.Paredes-Obando M, Moreno A, Panduro-García E, Ferreyra A, Chuquipiondo-Galdos D, Ascate JJV,518*et al.* Malaria cerebral con pancitopenia por *Plasmodium vivax* en la Amazonía peruana: reporte de519caso. *Rev Peru Med Exp Salud Pública* (2022) 39(2):241–4.
- Akhlaq A, Ghanchi NK, Usmani B, Shahzad R, Rahim A, Wasay M, *et al.* Neurological Complications in
   Patients with *Plasmodium Vivax* Malaria from Karachi, Pakistan. *Journal of the Royal College of Physicians of Edinburgh* (2018) 48(3):198–201.
- 523 15. Naing C, Whittaker MA, Nyunt Wai V, Mak JW. Is *Plasmodium vivax* Malaria a Severe Malaria?: A 524 Systematic Review and Meta-Analysis. *PLoS Negl Trop Dis* (2014) 8(8):e3071.
- 16. Rathia SK, Sankar J, Kandasamy D, Lodha R. *Plasmodium vivax* Malaria Presenting with Multifocal Hemorrhagic Brain Infarcts in a School-going Child. *J Trop Pediatr* (2016) 62(4):341–4.
- 527 17. Tanwar GS, Khatri PC, Sengar GS, Kochar A, Kochar SK, Middha S, *et al.* Clinical profiles of 13 528 children with *Plasmodium vivax* cerebral malaria. *Ann Trop Paediatr* (2011) 31(4):351–6.
- 18. Cox-Singh J, Hiu J, Lucas SB, Divis PC, Zulkarnaen M, Chandran P, *et al.* Severe malaria A case of fatal *Plasmodium knowlesi* infection with post-mortem findings: A case report. *Malar J* (2010) 9(1):1–7.
- Anstey NM, Grigg MJ, Rajahram GS, Cooper DJ, William T, Kho S, *et al.* Knowlesi malaria: Human risk
   factors, clinical spectrum, and pathophysiology. *Adv Parasitol* (2021) 113:1–43.
- 53320.Rajahram GS, Cooper DJ, William T, Grigg MJ, Anstey NM, Barber BE. Deaths From Plasmodium534knowlesi Malaria: Case Series and Systematic Review. Clin Infect Dis (2019) 69(10):1703–11.
- 535 21. Chuang H, Sakaguchi M, Lucky AB, Yamagishi J, Katakai Y, Kawai S, *et al.* SICA-mediated
   536 cytoadhesion of *Plasmodium knowlesi*-infected red blood cells to human umbilical vein endothelial
   537 cells. *Sci Rep* (2022) 12(1):1–12.
- 538 22. Mohanty S, Sahu PK, Pattnaik R, Majhi M, Maharana S, Bage J, *et al.* Evidence of Brain Alterations in 539 Noncerebral Falciparum Malaria. *Clin Infect Dis* (2022) 75(1):11–8.

- Sahu PK, Hoffmann A, Majhi M, Pattnaik R, Patterson C, Mahanta KC, *et al.* Brain Magnetic
   Resonance Imaging Reveals Different Courses of Disease in Pediatric and Adult Cerebral Malaria. *Clin Infect Dis* (2021) 73(7):e2387–96.
- Wang F, Zou ZR, Yuan D, Gong Y, Zhang L, Chen X, *et al.* Correlation between serum S100β protein
   levels and cognitive dysfunction in patients with cerebral small vessel disease: A case-control study.
   *Biosci Rep* (2017) 37(2).
- Rogan A, Sik A, Dickinson E, Patel V, Peckler B, McQuade D, *et al.* Diagnostic performance of S100B
  as a rule-out test for intracranial pathology in head-injured patients presenting to the emergency
  department who meet NICE Head Injury Guideline criteria for CT-head scan. *Emerg Med J* (2023)
  40(3):159–66.
- Conroy AL, Datta D, Hoffmann A, Wassmer SC. The kidney–brain pathogenic axis in severe falciparum malaria. *Trends Parasitol* (2023) 39(3):191–9.
- 552 27. Grigg MJ, William T, Barber BE, Rajahram GS, Menon J, Schimann E, *et al.* Age-Related Clinical
  553 Spectrum of *Plasmodium knowlesi* Malaria and Predictors of Severity. *Clin Infect Dis* (2018) 67(3):350–
  9.
- Jeslyn WPS, Huat TC, Vernon L, Irene LMZ, Sung LK, Jarrod LP, *et al.* Molecular epidemiological
   investigation of Plasmodium knowlesi in humans and macaques in Singapore. *Vector Borne Zoonotic Dis* (2011) 11(2):131–5.
- Noordin NR, Lee PY, Mohd Bukhari FD, Fong MY, Abdul Hamid MH, Jelip J, *et al.* Prevalence of
   Asymptomatic and/or Low-Density Malaria Infection among High-Risk Groups in Peninsular Malaysia.
   *Am J Trop Med Hyg* (2020) 103(3):1107–10.
- Westwood S, Baird AL, Anand SN, Nevado-Holgado AJ, Kormilitzin A, Shi L, *et al.* Validation of
   Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease
   Multimodal Biomarker Discovery Cohort. *J of Alzheimers Dis* (2020) 74(1):213–25.
- 56431.Ripamonti E, Edén A, Nilsson S, Sönnerborg A, Zetterberg H, Gisslén M. Longitudinal decline of565plasma neurofilament light levels after antiretroviral initiation in people living with HIV. J Intern Med566(2023) 293(4):445–56.
- Herman LS, Fornace K, Phelan J, Grigg MJ, Anstey NM, William T, *et al.* Identification and validation of
   a novel panel of *Plasmodium knowlesi* biomarkers of serological exposure. *PLoS Negl Trop Dis* (2018)
   12(6):e0006457.
- 570 33. Fornace KM, Herman LS, Abidin TR, Chua TH, Daim S, Lorenzo PJ, *et al.* Exposure and infection to
   571 *Plasmodium knowlesi* in case study communities in Northern Sabah, Malaysia and Palawan, The
   572 Philippines. *PLoS Negl Trop Dis* (2018) 12(6):e0006432.
- 573 34. Fornace KM, Brock PM, Abidin TR, Grignard L, Herman LS, Chua TH, et al. Environmental risk factors
  574 and exposure to the zoonotic malaria parasite *Plasmodium knowlesi* across northern Sabah, Malaysia:
  575 a population-based cross-sectional survey. *Lancet Planet Health* (2019) 3(4):e179–86.
- 57635.Longley RJ, White MT, Takashima E, Brewster J, Morita M, Harbers M, et al. Development and577validation of serological markers for detecting recent *Plasmodium vivax* infection. Nat Med (2020)57826(5):741–9.
- 57936.Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SLR, Carneiro I, *et al.* Estimating580medium- and long-term trends in malaria transmission by using serological markers of malaria581exposure. Proc Natl Acad Sci (2005) 102(14):5108–13.

- Rogier E, Nace D, Dimbu PR, Wakeman B, Pohl J, Beeson JG, *et al.* Framework for Characterizing
   Longitudinal Antibody Response in Children After *Plasmodium falciparum* Infection. *Front Immunol* (2021) 12:617951.
- Tetteh KKA, Wu L, Hall T, Ssewanyana I, Oulton T, Patterson C, *et al.* Optimisation and
   standardisation of a multiplex immunoassay of diverse *Plasmodium falciparum* antigens to assess
   changes in malaria transmission using sero-epidemiology. *Wellcome Open Res.* (2020) 4:26.
- 588 39. Michetti F, D'Ambrosi N, Toesca A, Puglisi MA, Serrano A, Marchese E, *et al.* The S100B story: from biomarker to active factor in neural injury. *J Neurochem* (2019) 148(2):168–87.
- 590 40. Mohanty S, Sahu PK, Pattnaik R, Majhi M, Maharana S, Bage J, *et al.* Evidence of Brain Alterations in 591 Noncerebral Falciparum Malaria. *Clin Infect Dis* (2022) 75(1):11–8.
- Kawata K, Liu CY, Merkel SF, Ramirez SH, Tierney RT, Langford D. Blood biomarkers for brain injury:
   What are we measuring? *Neurosci Biobehav Rev* (2016) 68:460–73.
- 594 42. Datta D, Bangirana P, Opoka RO, Conroy AL, Co K, Bond C, *et al.* Association of Plasma Tau With
   595 Mortality and Long-term Neurocognitive Impairment in Survivors of Pediatric Cerebral Malaria and
   596 Severe Malarial Anemia. *JAMA Netw Open* (2021) 4(12):e2138515–e2138515.
- Thelin EP, Zeiler FA, Ercole A, Mondello S, Büki A, Bellander BM, *et al.* Serial sampling of serum
   protein biomarkers for monitoring human traumatic brain injury dynamics: A systematic review. *Front Neurol* (2017) 8:277421.
- 44. Datta D, Gopinadhan A, Soto A, Bangirana P, Opoka RO, Conroy AL, *et al.* Blood biomarkers of
   neuronal injury in paediatric cerebral malaria and severe malarial anaemia. *Brain Commun* (2023)
   5(6):fcad323.
- 45. Zubelzu M, Morera-Herreras T, Irastorza G, Gómez-Esteban JC, Murueta-Goyena A. Plasma and
   serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis. *Parkinsonism Relat Disord* (2022) 99:107–15.
- 46. Çevik S, Özgenç MM, Güneyk A, Evran Ş, Akkaya E, Çalış F, *et al.* NRGN, S100B and GFAP levels
  are significantly increased in patients with structural lesions resulting from mild traumatic brain injuries. *Clin Neurol Neurosurg* (2019) 183:105380.
- 60947.Yang J, Korley FK, Dai M, Everett AD. Serum neurogranin measurement as a biomarker of acute610traumatic brain injury. Clin Biochem (2015) 48(13–14):843–8.
- 48. Dietrick B, Molloy E, Massaro AN, Strickland T, Zhu J, Slevin M, *et al.* Plasma and Cerebrospinal Fluid
   612 Candidate Biomarkers of Neonatal Encephalopathy Severity and Neurodevelopmental Outcomes. *J* 613 *Pediatr* (2020) 226:71-79.e5.
- 49. Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V, *et al.* Serum GFAP and
  615 UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre
  616 observational study. *Lancet Neurol* (2018) 17(9):782–9.
- 50. Eide PK, Lashkarivand A, Pripp A, Valnes LM, Hovd MH, Ringstad G, *et al.* Plasma neurodegeneration
   biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological
   disorders. *Nat Commun* (2023) 14(1):1–14.
- 51. Shen XN, Huang SY, Cui M, Zhao QH, Guo Y, Huang YY, *et al.* Plasma Glial Fibrillary Acidic Protein in
   the Alzheimer Disease Continuum: Relationship to Other Biomarkers, Differential Diagnosis, and
   Prediction of Clinical Progression. *Clin Chem* (2023) 69(4):411–21.

- 52. Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, *et al.* Differential levels of plasma
  biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal
  dementia and progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry* (2022) 93(6):651–8.
- Kim BY, Lee SH, Graham PL, Angelucci F, Lucia A, Pareja-Galeano H, *et al.* Peripheral Brain-Derived
   Neurotrophic Factor Levels in Alzheimer's Disease and Mild Cognitive Impairment: a Comprehensive
   Systematic Review and Meta-analysis. *Mol Neurobiol* (2017) 54(9):7297–311.
- 62954.Karimi N, Ashourizadeh H, Akbarzadeh Pasha B, Haghshomar M, Jouzdani T, Shobeiri P, *et al.* Blood630levels of brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis (MS): A systematic631review and meta-analysis. *Mult Scler Relat Disord* (2022) 65:103984.
- 632 55. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, *et al.* Multiplexed Immunoassay
   633 Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis. *PLoS One* 634 (2011) 6(4):e18850.
- 635 56. Abdi IY, Bartl M, Dakna M, Abdesselem H, Majbour N, Trenkwalder C, *et al.* Cross-sectional proteomic
  636 expression in Parkinson's disease-related proteins in drug-naïve patients vs healthy controls with
  637 longitudinal clinical follow-up. *Neurobiol Dis* (2023) 177:105997.
- 63857.Yang X, Zou M, Pang X, Liang S, Sun C, Wang J, *et al.* The association between NCAM1 levels and639behavioral phenotypes in children with autism spectrum disorder. *Behav Brain Res* (2019) 359:234–8.
- 64058.Zhao J, Lu W, Li J, Liu L, Zhao X. Decreased Serum NCAM Levels Associated with Cognitive641Impairment in Vascular Dementia. *Dis Markers* (2021) 2021:2792884.
- 59. Patra K, Soosaipillai A, Sando SB, Lauridsen C, Berge G, Møller I, *et al.* Assessment of kallikrein 6 as
  a cross-sectional and longitudinal biomarker for Alzheimer's disease. *Alzheimers Res Ther* (2018)
  10(1):1–11.
- 645 60. Jha MK, Lee S, Park DH, Kook H, Park KG, Lee IK, *et al.* Diverse functional roles of lipocalin-2 in the 646 central nervous system. *Neurosci Biobehav Rev* (2015) 49:135–56.
- 647 61. Sahu PK, Hoffmann A, Majhi M, Pattnaik R, Patterson C, Mahanta KC, *et al.* Brain Magnetic
  648 Resonance Imaging Reveals Different Courses of Disease in Pediatric and Adult Cerebral Malaria. *Clin*649 *Infect Dis* (2021) 73(7):e2387–96.
- 650 62. Balanza N, Francis CK, Crowley VM, Weckman AM, Zhong K, Baro B, *et al.* Neurofilament Light Chain 651 as a Biomarker of Neuronal Damage in Children With Malaria. *J Infect Dis* (2024) 229(1):183–8.
- 63. Chen Y, Chan CK, Kerishnan JP, Lau YL, Wong YL, Gopinath SCB. Identification of circulating
  biomarkers in sera of *Plasmodium knowlesi*-infected malaria patients comparison against *Plasmodium vivax* infection. *BMC Infect Dis* (2015) 15(1):1–10.
- 65564.Wenisch C, Linnau KF, Looaresuwan S, Rumpold H. Plasma Levels of the Interleukin-6 Cytokine656Family in Persons with Severe Plasmodium falciparum Malaria. J Infect Dis [Internet]. 1999 Mar 1 [cited6572023 Nov 8];179(3):747–50. Available from: https://dx.doi.org/10.1086/314630
- 65. De Jong GM, Slager JJ, Verbon A, Van Hellemond JJ, Van Genderen PJJ. Systematic review of the
   role of angiopoietin-1 and angiopoietin-2 in Plasmodium species infections: biomarkers or therapeutic
   targets? *Malar J* (2016) 15(1):1–12.
- 66. Jain V, Lucchi NW, Wilson NO, Blackstock AJ, Nagpal AC, Joel PK, *et al.* Plasma levels of
  662 angiopoietin-1 and -2 predict cerebral malaria outcome in Central India. *Malar J* (2011) 10(1):1–7.
- 663
  67. Gomes LT, Alves- ER, Rodrigues-Jesus C, Nery AF, Gasquez-Martin TO, Fontes CJ. Angiopoietin-2
  664
  665
  665
  667
  668
  668
  669
  669
  669
  660
  660
  660
  660
  660
  661
  661
  661
  662
  662
  663
  664
  665
  665
  665
  665
  665
  665
  665
  666
  666
  667
  668
  668
  668
  669
  669
  669
  669
  660
  660
  660
  660
  660
  660
  660
  661
  661
  662
  662
  663
  664
  665
  665
  665
  664
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665
  665</l

- 666
  68. Jain V, Thomas T, Basak S, Sharma RK, Singh N. Sequential dysregulated plasma levels of
  667
  668
  668
  669
  669
  669
  660
  660
  661
  662
  663
  664
  665
  665
  665
  665
  666
  666
  666
  667
  667
  668
  668
  669
  668
  669
  669
  669
  669
  669
  669
  669
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  660
  <li
- 670 69. Oluboyo AO, Chukwu SI, Oluboyo BO, Odewusi OO. Evaluation of Angiopoietins 1 and 2 in Malaria-671 Infested Children. *J Environ Public Health* (2020) 2020:2169763.
- 672 70. Conroy AL, Lafferty EI, Lovegrove FE, Krudsood S, Tangpukdee N, Liles WC, *et al.* Whole blood
  673 angiopoietin-1 and-2 levels discriminate cerebral and severe (non-cerebral) malaria from
  674 uncomplicated malaria. *Malar J* (2009) 8(1):1–7.
- 675 71. Ouma BJ, Ssenkusu JM, Shabani E, Datta D, Opoka RO, Idro R, *et al.* Endothelial Activation, Acute
  676 Kidney Injury, and Cognitive Impairment in Pediatric Severe Malaria. *Crit Care Med* (2020)
  677 48(9):E734–43.
- Raza A, Ghanchi NK, Zubairi ABS, Raheem A, Nizami S, Beg MA. Tumor Necrosis Factor -α,
  Interleukin-10, Intercellular and Vascular Adhesion Molecules Are Possible Biomarkers of Disease
  Severity in Complicated *Plasmodium vivax* Isolates from Pakistan. *PLoS One* (2013) 8(12):e81363.
- Fernandez-Camacho B, Peña-Calero B, Guillermo-Roman M, Ruiz-Cabrejos J, Barboza JL, Bartolini Arana L, *et al.* Malaria seroepidemiology in very low transmission settings in the Peruvian Amazon. *Sci Rep* (2024) 14(1):1–14.
- 684 74. Pinkevych M, Petravic J, Chelimo K, Kazura JW, Moormann AM, Davenport MP. The Dynamics of
  685 Naturally Acquired Immunity to *Plasmodium falciparum* Infection. *PLoS Comput Biol* (2012)
  686 8(10):e1002729.
- 687 75. Chiu PY, Yang FC, Chiu MJ, Lin WC, Lu CH, Yang SY. Relevance of plasma biomarkers to
  688 pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia. *Sci Rep* (2022)
  689 12(1):1–9.
- 690 76. Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, *et al.* High performance plasma amyloid-β biomarkers for Alzheimer's disease. *Nature* (2018) 554(7691):249–54.
- 692 77. Cheng L, Li W, Chen Y, Lin Y, Wang B, Guo Q, *et al.* Plasma Aβ as a biomarker for predicting Aβ-PET
   693 status in Alzheimer's disease : a systematic review with meta-analysis. *J Neurol Neurosurg Psychiatry* 694 (2022) 93(5):513–20.
- Rodríguez-Rodríguez A, Egea-Guerrero JJ, Gordillo-Escobar E, Enamorado-Enamorado J,
  Hernández-García C, Ruiz de Azúa-López Z, *et al.* S100B and Neuron-Specific Enolase as mortality
  predictors in patients with severe traumatic brain injury. *Neurol Res* (2016) 38(2):130–7.
- Böhmer AE, Oses JP, Schmidt AP, Perón CS, Krebs CL, Oppitz PP, *et al.* Neuron-specific enolase,
  S100B, and glial fibrillary acidic protein levels as outcome predictors in patients with severe traumatic
  brain injury. *Neurosurgery* (2011) 68(6):1624–30.
- 70180.Li X, Wang X, Guo L, Wu K, Wang L, Rao L, et al. Association between lipocalin-2 and mild cognitive702impairment or dementia: A systematic review and meta-analysis of population-based evidence. Ageing703Res Rev (2023) 89:101984.
- 81. Shi Y, Luan D, Song R, Zhang Z. Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis. *Eur* 706 *Neuropsychopharmacol* (2020) 41:40–51.
- Qin XY, Wu HT, Cao C, Loh YP, Cheng Y. A meta-analysis of peripheral blood nerve growth factor
   levels in patients with schizophrenia. *Mol Psychiatry* (2017) 22(9):1306–12.

- 70983.Gao W, Zhang Z, Lv X, Wu Q, Yan J, Mao G, et al. Neurofilament light chain level in traumatic brain710injury: A system review and meta-analysis. Medicine (2020) 99(38):e22363.
- 711 84. Zhao Y, Xin Y, Meng S, He Z, Hu W. Neurofilament light chain protein in neurodegenerative dementia:
  712 A systematic review and network meta-analysis. *Neurosci Biobehav Rev* (2019) 102:123–38.
- 85. Katunina EA, Blokhin V, Nodel MR, Pavlova EN, Kalinkin AL, Kucheryanu VG, *et al.* Searching for
  Biomarkers in the Blood of Patients at Risk of Developing Parkinson's Disease at the Prodromal Stage. *Int J Mol Sci* (2023) 24(3):1842.
- Rogan A, O'Sullivan MB, Holley A, McQuade D, Larsen P. Can serum biomarkers be used to rule out significant intracranial pathology in emergency department patients with mild traumatic brain injury? A Systemic Review & Meta-Analysis. *Injury* (2022) 53(2):259–71.
- Wang F, Zou ZR, Yuan D, Gong Y, Zhang L, Chen X, *et al.* Correlation between serum S100β protein
   levels and cognitive dysfunction in patients with cerebral small vessel disease: A case-control study.
   *Biosci Rep* (2017) 37(2):BSR20160446.
- Katisko K, Huber N, Kokkola T, Hartikainen P, Krüger J, Heikkinen AL, *et al.* Serum total TDP-43 levels
  are decreased in frontotemporal dementia patients with C9orf72 repeat expansion or concomitant
  motoneuron disease phenotype. *Alzheimers Res Ther* (2022) 14(1):1–10.
- 72589.Ren Y, Li S, Chen S, Sun X, Yang F, Wang H, et al. TDP-43 and Phosphorylated TDP-43 Levels in726Paired Plasma and CSF Samples in Amyotrophic Lateral Sclerosis. Front Neurol (2021) 12:663637.
- 72790.Villaverde C, Namazzi R, Shabani E, Park GS, Datta D, Hanisch B, et al. Retinopathy-Positive728Cerebral Malaria Is Associated With Greater Inflammation, Blood-Brain Barrier Breakdown, and729Neuronal Damage Than Retinopathy-Negative Cerebral Malaria. J Pediatric Infect Dis Soc (2020)7309(5):580–6.
- Datta D, Conroy AL, Castelluccio PF, Ssenkusu JM, Park GS, Opoka RO, *et al.* Elevated
  Cerebrospinal Fluid Tau Protein Concentrations on Admission Are Associated With Long-term
  Neurologic and Cognitive Impairment in Ugandan Children With Cerebral Malaria. *Clin Infect Dis*(2020) 70(6):1161–8.
- Frdman LK, Petes C, Lu Z, Dhabangi A, Musoke C, Cserti-Gazdewich CM, et al. Chitinase 3-like 1 is
  induced by *Plasmodium falciparum* malaria and predicts outcome of cerebral malaria and severe
  malarial anaemia in a case-control study of African children. *Malar J* (2014) 13(1):1–11.
- Conroy AL, Hawkes MT, Elphinstone R, Opoka RO, Namasopo S, Miller C, *et al.* Chitinase-3-like 1 is a
   biomarker of acute kidney injury and mortality in paediatric severe malaria. *Malar J* (2018) 17(1):1–11.
- 740

#### 742 **11 Figure legends**

# 743 **Figure 1. Sample collection sites.**

Samples from *Pk*-infected patients were collected from government hospitals and private clinics in Johor, Selangor, Pahang, Perak, and Trengganu states (red). Samples from community-matched, age-matched uninfected controls were collected via active sample screening of communities in Johor, Selangor, Negeri Sembilan, and Kedah (yellow). Map was created in R with RStudio using Leaflet (<u>https://leafletjs.com/</u>) and OpenStreetMap (<u>https://www.openstreetmap.org</u>). An interactive version of the map can be found in GitHub (<u>https://github.com/Cescualito/LSHTM\_Wassmer\_Pknowlesi\_Malaysia</u>).

# 750 Figure 2. Group comparisons: Levels of blood circulating biomarkers of brain injury.

751  $\alpha$ Syn: alpha-Synuclein; APP: amyloid-beta precursor protein; A $\beta_{1-42}$ : amyloid beta (1-42); BDNF: brain-752 derived neurotrophic factor; CaBP: Calbindin D; CNS: central nervous system; CNTF: ciliary neurotrophic 753 factor; CNTN1: contactin-1; CSF: cerebrospinal fluid; ENO2 / NSE: Enolase 2 / Neuron-specific Enolase; 754 AHSG: alpha 2-HS glycoprotein; FGF-21: fibroblast growth factor 21; GDNF: glial cell line-derived 755 neurotrophic factor; GFAP: glial fibrillary acidic protein; KLK6: kallikrein 6 / neurosin; NCAM-1: neural cell 756 adhesion molecule; NGAL: neutrophil gelatinase-associated lipocalin (also known as Lipocalin-2); NGF-β: 757 nerve growth factor beta; NfL: neurofilament light chain; NRGN: neurogranin; Park7: Parkinsonism-associated 758 deglycase; RNA: ribonucleic acid; S100ß: S100 calcium-binding protein ß; TDP-43: TAR DNA-binding protein 759 43; Tau: total Tau protein; Tau pT181: phosphorylated Tau protein; UCH-L1: ubiquitin carboxy-terminal 760 hydrolase L1; YKL40: Chitinase-3-like protein 1. Wilcoxon test results: \*p<0.05; \*\*p<0.01; \*\*\*p<0.001; 761 \*\*\*\*p<0.0001; ns: no significance.

#### 762 Figure 3. Hierarchical clustering heatmaps: Distinct circulating biomarker profiles between groups.

Fig 3A. Biomarkers of brain alterations or cerebral injury: αSyn: alpha-Synuclein; APP: amyloid-beta
precursor protein; Aβ<sub>1-42</sub>: amyloid beta (1-42); BDNF: brain-derived neurotrophic factor; CaBP: Calbindin D;
CNTN1: contactin-1; CSF: cerebrospinal fluid; ENO2 / NSE: Enolase 2 / Neuron-specific Enolase; GFAP: glial
fibrillary acidic protein; KLK6: kallikrein 6 / neurosin; NCAM-1: neural cell adhesion molecule; Lipocalin-2:
neutrophil gelatinase-associated lipocalin; NGF-β: nerve growth factor beta; NfL: neurofilament light chain;
NRGN: neurogranin; Park7: Parkinsonism-associated deglycase; S100B: S100 calcium-binding protein β;

**TDP-43**: TAR DNA-binding protein 43; **Tau**: total Tau protein; **UCH-L1**: ubiquitin carboxy-terminal hydrolase

T70 L1; **YKL40**: Chitinase-3-like protein 1.

**Fig 3B. Biomarkers of infection and immune activation**: **CCL2**: chemokine (C-C motif) ligand 2; **CCL4**: chemokine (C-C motif) ligands 4; **CCL5**: chemokine (C-C motif) ligand 5; **CCL18**: chemokine (C-C motif) ligand 18; **CRP**: C-reactive protein; **GM-CSF**: granulocyte-macrophage colony-stimulating factor; **IFN-** $\gamma$ : interferon gamma; **IL-1** $\alpha$ : interleukin 1 alpha; **IL-1** $\beta$ : interleukin 1 beta; **IL-1RA**: interleukin 1RA; **IL-2**: interleukin 2; **IL-4**: interleukin 4; **IL-6**: interleukin 6; **IL-8**: interleukin 8; **IL-10**: interleukin 10; **IL-17A**: interleukin 17; **MIF**: migration inhibitory factor; **MPO**: myeloperoxidase; **OPN**: osteopontin; **RAGE**: receptor for advanced glycation end-products; **TNF-** $\alpha$ : tumour Necrosis Factor alpha.

Fig 3C. Vascular biomarkers: Ang-1: angiopoietin-1; Ang-2: angiopoietin-2; Ang-2/Ang-1: ratio between
Ang-2 and Ang-1; BMP-9: bone morphogenetic protein 9; ICAM-1: intercellular adhesion molecule 1; PDGFAA: platelet-derived growth factor AA; PDGF-BB: platelet-derived growth factor BB; Serpin E1: Serine
Proteinase Inhibitor<sup>®</sup> clade E1; VCAM-1: vascular cell adhesion molecule; VEGF: vascular endothelial growth
factor; vWF-A2: von Willebrand Factor (A2 domain). Data is scaled.

783

# 784 **12 Table legends**

# 785 **Table 1. Plasma biomarkers of brain alterations or cerebral injury.**

786  $\alpha$ Syn: alpha-Synuclein; APP: amyloid-beta precursor protein; A $\beta_{1-42}$ : amyloid beta (1-42); BDNF: brain-787 derived neurotrophic factor; CaBP: Calbindin D; CNS: central nervous system; CNTF: ciliary neurotrophic 788 factor; CNTN1: contactin-1; CSF: cerebrospinal fluid; ENO2 / NSE: Enolase 2 / Neuron-specific Enolase; 789 AHSG: alpha 2-HS alvcoprotein: FGF-21: fibroblast growth factor 21: GDNF: alial cell line-derived 790 neurotrophic factor; GFAP: glial fibrillary acidic protein; KLK6: kallikrein 6 / neurosin; NCAM-1: neural cell 791 adhesion molecule; NGAL: neutrophil gelatinase-associated lipocalin (also known as Lipocalin-2); NGF-ß: 792 nerve growth factor beta; NfL: neurofilament light chain; NRGN: neurogranin; Park7: Parkinsonism-associated 793 deglycase; **RNA**: ribonucleic acid; **S100β**: S100 calcium-binding protein β; **TDP-43**: TAR DNA-binding protein 794 43; Tau: total Tau protein; Tau pT181: phosphorylated Tau protein; UCH-L1: ubiquitin carboxy-terminal 795 hydrolase L1; YKL40: Chitinase-3-like protein 1. Biomarker descriptions are extracted from UniProt 796 (www.uniprot.org, last accessed January 2024).

- 797 Legend: Clinical findings related to: A Plasmodium falciparum malaria infection; A Plasmodium knowlesi
- 798 malaria infection; P Neurological conditions.

799 Figure 1. Sample collection sites.



Figure 2. Group comparisons: Levels of blood circulating biomarkers of brain alterations or cerebral injury.



Figure 3. Hierarchical clustering heatmaps: Distinct circulating biomarker profiles between groups.







Table 1	Plasma biomarkers of brain alterations or cerebral injury				
Marker	Description	Clini	cal significance		
αSyn	Neuronal intracellular protein. Regulates synaptic vesicle trafficking and neurotransmitter release. Its aggregation in the brain is associated with neurodegeneration.	9	Plasma $\alpha$ Syn levels were higher in Parkinson's Disease patients than healthy controls and patients w neurodegenerative diseases (45,75).		
APP	Neuronal transmembrane protein. Involved in the generation of synapses and axons, neurite growth, and neuronal adhesion. Undergoes proteolytic processes to generate $A\beta$ .	•	In Japanese and Australian cohorts encompassing cognitively normal individuals, subjects with mild c impairment, and Alzheimer's Disease patients, plasma APP/Aβ ratio predicted individual brain Aβ s determined by PET imaging (76).		
Αβ <sub>1-42</sub>	APP-derived peptide. The imbalance between $A\beta$ production and clearance, its misfolding, and accumulation in the extracellular space, are early factors in Alzheimer's disease.	9	Lower A $\beta_{1-42}$ plasma levels were associated with A $\beta$ deposition in the brain of patients with varied decognitive decline, compared with other groups (77).		
BDNF	Neurotrophic factor. Major regulator of synaptic transmission and plasticity in adult synapses. Homeostatic regulator of intrinsic neuronal excitability.	9	Compared with healthy controls, plasma BDNF levels were increased in patients with certain condi such as early Alzheimer's Disease— and decreased in patients diagnosed of multiple sclerosis (53,54)		
CaBP	Cytosolic protein. Binds calcium with high affinity and regulates its availability in the cytoplasm, playing a role in transepithelial calcium transport.	9	Increased CSF levels could predict risk of future dementia in US patients who were cognitively normatime of recruitment (55).		
CNTN1	Membrane protein, participates in nervous system development and neuronal-glia interactions in myelinated nerves.	9	Compared to healthy patients, downregulated CNTN1 serum levels predicted cognitive and motor in German patients with Parkinson's Disease (56).		
ENO2 / NSE	Dimeric isoform of enolase, an enzyme involved in the metabolic process of glycolysis, relatively specific to neurons.	9	Plasma levels are significantly higher in patients with traumatic brain injury, compared with healthy (43,78,79).		
Fetuin A	Serum glycoprotein, produced by hepatocytes, adipocytes, and choroid plexus cells. Involved in brain development, endocytosis, and bone tissue formation.	Å	Compared with healthy controls, serum levels were significantly higher in Malaysian patients with k malaria, as revealed by two-dimensional electrophoresis and mass spectrometry analysis (63).		
GFAP	Intermediate filament protein, specific to astrocytes. Involved in cell-cell communication and blood brain barrier functioning.	9	Used in clinical settings to determine injury severity and case management after traumatic brain injury		
		9	In Norwegian patients with CSF disorders, higher plasma GFAP concentrations were associated with i glymphatic function (50).		
		9	In Chinese and UK cohorts, plasma GFAP level ranges distinguished patients with neurodegenerative diseases (51,52).		
KLK6	Serine protease, also known as neurosin. Participates in degradation processes against proteins such as APP or $\alpha$ Syn.	9	Plasma levels were significantly increased in Swedish patients with advanced Alzheimer's Disease, cc with healthy controls (59).		
NCAM-1	Cell surface glycoprotein, expressed in neurons and glia. Involved in cell-cell adhesion, neurite outgrowth, synaptic plasticity, learning, and memory.	9	Plasma levels were significantly lower in Chinese children with autistic spectrum disorder. Leve negatively correlated with a battery of neurocognitive scores (57).		

NGAL	Iron-trafficking protein. Participates in innate immunity by binding iron and impeding its uptake by bacteria, which limits their growth. Also plays a role in renal development.	入 〇	Compared with uncomplicated cases, plasma levels were significantly higher in Indian adults with <i>fai</i> cerebral malaria and discriminated between fatal and nonfatal outcomes (61).	
		9	Compared with non-dementia controls, plasma levels are significantly higher in patients with Alzl Disease (80).	
NGF-β	Neurotrophic factor. Regulates proliferation, differentiation, and survival of sympathetic and sensory neurons.	9	Compared with healthy controls, plasma levels are lower in patients with major depressive disorde patients with schizophrenia (81,82).	
NfL	Subunit of intermediate filament proteins, exclusive to neurons. Highly expressed in axons, also present in dendrites and neuronal bodies.	永 會	Plasma levels were significantly higher in Ugandan children with falciparum cerebral malaria and malarial anaemia, compared with asymptomatic community children. Elevated levels associated wit cognitive outcomes and mortality in children with cerebral malaria (44).	
		<u></u>	Longitudinal analysis in Mozambican children with uncomplicated and severe falciparum malaria revea while plasma levels were similar upon admission, they increased over time, particularly in severe cases with neurological symptoms (62).	
		9	Increased plasma levels are detected in patients with traumatic or vascular injury, neuroinflammati neurodegeneration (43,83,84).	
NRGN	Postsynaptic neuronal protein, expressed primarily in dendritic spines. Involved in the protein kinase C signalling pathway, regulates calmodulin availability.	9	Compared with healthy newborns, plasma levels were significantly higher in Irish babies with r encephalopathy, and they were inversely associated with neurodevelopmental cognitive, motor, and la scores (48).	
		9	Serum concentrations were significantly higher in Turkish and US patients with mild and acute trauma injury, respectively, when compared with healthy controls (46,47).	
Park7	Enzyme found in many tissues and organs, including the brain. Has a protective role against oxidative stress and cell death.	9	Compared to those of healthy controls, lymphocytes from patients at risk of developing prodromal Par Disease showed a decrease in the expression of Park7 (85).	
S100β	Neurotrophic factor. Promotes astrogliosis and axonal proliferation. Highly expressed in astrocytes, it is one of the most abundant soluble proteins in the brain.	9	Increased plasma levels serve as a blood biomarker of cerebral small vessel disease and intracrani (39,86,87).	
		*	Plasma levels were increased in Indian patients with falciparum severe malaria, compared with uncom cases (40).	
TDP-43	RNA-binding protein. Regulates the processing of RNAs involved in neuronal survival, as well as mRNAs that encode proteins relevant for neurodegenerative diseases.	9	Serum levels are decreased in patients with certain neurodegenerative diseases, such as frontot dementia (88) and increased in other pathologies, such as sporadic amyotrophic lateral sclerosis (89).	
Tau	Microtubule-associated protein, used as a biomarker of neuronal injury. Promotes microtubule assembly and stability, involved in neuronal polarity. Forms insoluble	<i>እ</i> ወ	Plasma levels were increased in Ugandan children with falciparum cerebral malaria or severe anaemia, compared with healthy controls. Plasma levels were associated with mortality and pe	

# Brain injury biomarkers in P. knowlesi infe

	filaments that accumulate as neurofibrillary tangles in Alzheimer's Disease.		neurocognitive impairment in young children with cerebral malaria (42).	
		<u>ት</u>	In Ugandan children with falciparum cerebral malaria, elevated CSF levels were associated with in disease severity, malaria retinopathy, acute kidney injury, prolonged coma duration, and persist neurologic deficits up to 2 years post-discharge (90,91).	
UCH-L1	Ubiquitin-protein hydrolase. Processes ubiquitin precursors and ubiquitinated proteins. Associated with neurofibrillary tangles in Alzheimer's Disease.	入 〇	Plasma levels were significantly higher in Ugandan children with falciparum cerebral malaria and malarial anaemia, compared with asymptomatic community children. Elevated levels were linked to brain barrier dysfunction and neurodeficits over follow-up (44).	
YKL-40	Glycoprotein secreted by macrophages and other inflammatory cells during differentiation.	<u>አ</u> ዓ	In Ugandan children with falciparum malaria, plasma levels were significantly increased in severe anaemia and cerebral malaria versus uncomplicated malaria. Among severe cases, admission plasm predicted mortality with high sensitivity and specificity (92).	
		入	In Ugandan children with severe <i>falciparum</i> malaria, admission plasma levels were elevated in cas subsequently died. Levels correlated with markers of inflammation and endothelial activation (93).	